Monte Rosa Therapeutics, Inc. (GLUE) Stock Price & Analysis
Monte Rosa Therapeutics, Inc. (GLUE) fell 1.09% to USD 22.78 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
GLUE last closed at USD 23.03; the session ranged USD 22.37–24.17 on volume of 851,020 shares. Market capitalization is $1.92B, with a 52-week range of USD 4.12–25.77 (NMS). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 22.78 |
|---|---|
| Change | ▼ 1.09% (down) |
| Previous Close | USD 23.03 |
| Open | USD 23.27 |
| Day Range | USD 22.37 – 24.17 |
| 52-Week Range | USD 4.12 – 25.77 |
| Volume | 851,020 shares |
| Market Cap | $1.92B |
| Exchange | NMS |
Technical Analysis (GLUE)
Nexqual's technical model rates GLUE "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 55.43 (neutral) |
| vs SMA50 | Above (USD 20.5) |
| MACD | 0.79 (positive) |
Analyst Ratings (GLUE)
Wall Street analysts rate GLUE "Strong Buy" based on 6 analysts, with a mean price target of USD 33.17 (range USD 29–37), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 33.17 |
| High Target | USD 37 |
| Low Target | USD 29 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (GLUE)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.37 |
| Revenue Estimate | $12.88M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.45 vs est -0.38 ▼ miss |
| 2025-12-31 | USD -0.55 vs est -0.34 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.35 ▲ beat |
| 2025-06-30 | USD -0.15 vs est -0.36 ▲ beat |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (GLUE)
| Total Revenue | $42.95M |
|---|---|
| Revenue Growth (YoY) | -95.00% |
| Gross Margin | -238.54% |
| Operating Margin | -1188.46% |
| Profit Margin | +0.00% |
| ROE | -32.62% |
| Debt / Equity | 7.49 |
| Current Ratio | 9.54 |
| Total Cash | $666.22M |
| Total Debt | $39.06M |
| Free Cash Flow | $-61.15M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (GLUE)
Nexqual rates Monte Rosa Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Strong — Revenue +64% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $666M cash vs $39M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$61M, burning cash |
| Efficiency | Critical — ROE -33%, ROA -16.4% |
Ownership (GLUE)
| Insider Ownership | +0.57% |
|---|---|
| Institutional Ownership | +113.43% |
| Shares Outstanding | 84.48M |
| Float | 54.02M |
| Short % of Float | +22.41% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (GLUE)
Monte Rosa Therapeutics, Inc. is led by Markus Warmuth (age 54), President, CEO & Director, per Nexqual as of July 25, 2026 at 02:21 UTC.
| President, CEO & Director | Markus Warmuth (age 54) |
|---|---|
| Chief Operating Officer | Jennifer Champoux (age 53) |
| Chief Technology Officer | Magnus Walter DPHIL |
| Chief Scientific Officer | Sharon Townson (age 50) |
Major Backers & Investors (GLUE)
Notable institutional backers of Monte Rosa Therapeutics, Inc. include NEA Management Company, LLC, Price (T.Rowe) Associates Inc, TCG Crossover Management, LLC, according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| NEA Management Company, LLC | 9.11% |
| Price (T.Rowe) Associates Inc | 9.02% |
| TCG Crossover Management, LLC | 5.47% |
| BVF Inc. | 5.28% |
| T. Rowe Price | 5.23% |
| Baker Bros. Advisors, LP | 5.14% |
| Suvretta Capital Management, LLC | 5% |
| Vestal Point Capital, LP | 4.27% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.38% |
| State Street | 6.46% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
From Monte Rosa Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
- The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
- In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast.
- Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | USD 2.11 | ▼ 1.86% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
| ERAS | Erasca, Inc. | USD 19.11 | ▼ 2.05% |
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
| CGEM | Cullinan Therapeutics, Inc. | USD 17.1 | ▼ 3.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.